Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2020

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregated Revenue

The Company's significant therapeutic classes for its Generics and Specialty segments and sales channels for its AvKARE segment, as determined based on net revenue for each of the three and six months ended June 30, 2020 and 2019 are set forth below (in thousands):

		Three Months Ended June 30,				Six Months Ended June 30,
		2020		2019		2020		2019
Generics
	Anti-Infective	$	9,722	$	8,147	$	22,776	$	14,089
	Hormonal/Allergy	89,277		92,293		177,919		195,018
	Antiviral	955		1,346		16,779		15,802
	Central Nervous System (1)	96,228		117,398		195,810		242,173
	Cardiovascular System	25,105		31,138		54,359		67,355
	Gastroenterology	16,625		9,938		37,878		19,494
	Oncology	16,567		21,746		31,422		36,705
	Metabolic Disease/Endocrine	6,769		10,887		23,408		28,734
	Respiratory	7,240		8,418		17,328		17,636
	Dermatology	10,442		14,771		27,584		27,744
	Other therapeutic classes	26,668		15,263		51,935		33,440
	International and other	961		3,719		1,947		19,351
	Total Generics net revenue	306,559		335,064		659,145		717,541
Specialty
	Hormonal/Allergy	13,669		9,888		27,623		20,787
	Central Nervous System (1)	74,056		50,694		142,367		93,593
	Gastroenterology	439		452		487		933
	Metabolic Disease/Endocrine	203		89		476		630
	Other therapeutic classes	5,889		8,455		11,280		17,278
	Total Specialty net revenue	94,256		69,578		182,233		133,221
AvKARE
	Distribution	31,839		—		63,425		—
	Government Label	25,073		—		46,451		—
	Institutional	4,511		—		7,924		—
	Other	2,424		—		4,017		—
	Total AvKARE net revenue	63,847		—		121,817		—
	Total net revenue	$	464,662	$	404,642	$	963,195	$	850,762

(1)During the three months ended September 30, 2019, operating results for Oxymorphone were reclassified from Generics to Specialty, where it is sold as a non-promoted product.  Prior period results have not been restated to reflect the reclassification.

Schedule of Major Categories of Sales-Related Deductions

A rollforward of the major categories of sales-related deductions for the six months ended June 30, 2020 is as follows (in thousands):

	Contract Charge - Backs and Sales Volume Allowances		Cash Discount Allowances		Accrued Returns Allowance		Accrued Medicaid and Commercial Rebates
Balance at December 31, 2019	$	829,807	$	34,308	$	150,361	$	114,960
Impact from the Acquisitions	12,444		944		15,229		10
Provision related to sales recorded in the period	2,025,733		60,000		49,285		69,685
Credits/payments issued during the period	(2,197,368)		(71,093)		(52,202)		(63,062)
Balance at June 30, 2020	$	670,616	$	24,159	$	162,673	$	121,593